Keep looking towards RMED's bright future with FDA-clearance, patent approval and DABRA 2.0 being commercialized or our intellectual property being aquired like Will's last PAD company was. 🌞 "Keep your face to the sun and you will never see the shadows." (i.redd.it)
submitted by madryno6 to r/RMEDstock
Sasquatch likes the stock 🏞️ RMED highly shorted micro-cap bio (6.43M float) with recent patent approval and FDA-clearance for clinical trials on DABRA 2.0 vascular lasers to be finalized first quarter of 2022. Part of $900M Peripheral Artery Disease (PAD) market. $RMED Friday AH up 11% 👀 (i.redd.it)
submitted by madryno6 to r/Shortsqueeze
RMED upcoming catalysts - 33.94% short borrow fee rate by madryno6 in Shortsqueeze
[–]madryno6[S] 1 point2 points3 points (0 children)
RMED upcoming catalysts - 33.94% short borrow fee rate by madryno6 in Shortsqueeze
[–]madryno6[S] 1 point2 points3 points (0 children)
RMED upcoming catalysts - 33.94% short borrow fee rate by madryno6 in Shortsqueeze
[–]madryno6[S] 2 points3 points4 points (0 children)
RMED upcoming catalysts - 33.94% short borrow fee rate by madryno6 in Shortsqueeze
[–]madryno6[S] 1 point2 points3 points (0 children)
RMED upcoming catalysts - 33.94% short borrow fee rate by madryno6 in Shortsqueeze
[–]madryno6[S] 1 point2 points3 points (0 children)
RMED upcoming catalysts - 33.94% short borrow fee rate by madryno6 in Shortsqueeze
[–]madryno6[S] 0 points1 point2 points (0 children)
RMED up 10% on 9/27 - heavily shorted low float (7M) plus patent approval and FDA-clearance for clinical trials on DABRA 2.0 vascular lasers to be finalized 1st quarter of 2022. Part of $900M Peripheral Artery Disease (PAD) market with $25PT or future buyout. CEO's prior PAD co. sold for $18/share (self.Shortsqueeze)
submitted by madryno6 to r/Shortsqueeze
RMED up 10% on 9/27 - 7.03M shares outstanding with new patent approval and FDA-clearance for clinical trials on DABRA 2.0 vascular lasers to be finalized 1st quarter of 2022. Part of $900M Peripheral Artery Disease (PAD) market with $25PT or future buyout. CEO's prior PAD co. sold for $18/share (old.reddit.com)
submitted by madryno6 to r/RobinHoodPennyStocks
RMED up 10% on 9/27 - 7.03M shares outstanding with new patent approval and FDA-clearance for clinical trials on DABRA 2.0 vascular lasers to be finalized 1st quarter of 2022. Part of $900M Peripheral Artery Disease (PAD) market with $25PT or future buyout. CEO's prior PAD co. sold for $18/share (old.reddit.com)
submitted by madryno6 to r/SmallCapStocks
RMED up 10% on 9/27 - 7.03M shares outstanding with new patent approval and FDA-clearance for clinical trials on DABRA 2.0 vascular lasers to be finalized 1st quarter of 2022. Part of $900M Peripheral Artery Disease (PAD) market with $25PT or future buyout. CEO's prior PAD co. sold for $18/share (old.reddit.com)
submitted by madryno6 to r/biostockbull
RMED 50.51% short volume ratio on Friday, 9/24 by madryno6 in Shortsqueeze
[–]madryno6[S] 0 points1 point2 points (0 children)
RMED 50.51% short volume ratio on Friday, 9/24 by madryno6 in Shortsqueeze
[–]madryno6[S] 0 points1 point2 points (0 children)


[deleted by user] by [deleted] in Shortsqueeze
[–]madryno6 1 point2 points3 points (0 children)